
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comprehensive analysis of the clinical immuno-oncology landscape
Jun Tang, A. Shalabi, Vanessa M. Hubbard-Lucey
Annals of Oncology (2017) Vol. 29, Iss. 1, pp. 84-91
Open Access | Times Cited: 471
Jun Tang, A. Shalabi, Vanessa M. Hubbard-Lucey
Annals of Oncology (2017) Vol. 29, Iss. 1, pp. 84-91
Open Access | Times Cited: 471
Showing 1-25 of 471 citing articles:
The Immune Landscape of Cancer
Vésteinn Thórsson, David L. Gibbs, Scott D. Brown, et al.
Immunity (2018) Vol. 48, Iss. 4, pp. 812-830.e14
Open Access | Times Cited: 4557
Vésteinn Thórsson, David L. Gibbs, Scott D. Brown, et al.
Immunity (2018) Vol. 48, Iss. 4, pp. 812-830.e14
Open Access | Times Cited: 4557
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei, Colm R. Duffy, James P. Allison
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1069-1086
Open Access | Times Cited: 2588
Spencer C. Wei, Colm R. Duffy, James P. Allison
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1069-1086
Open Access | Times Cited: 2588
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde, Daniel S. Chen
Immunity (2020) Vol. 52, Iss. 1, pp. 17-35
Open Access | Times Cited: 1606
Priti S. Hegde, Daniel S. Chen
Immunity (2020) Vol. 52, Iss. 1, pp. 17-35
Open Access | Times Cited: 1606
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed, Lieping Chen
Cell (2018) Vol. 175, Iss. 2, pp. 313-326
Open Access | Times Cited: 1192
Miguel F. Sanmamed, Lieping Chen
Cell (2018) Vol. 175, Iss. 2, pp. 313-326
Open Access | Times Cited: 1192
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
Christopher B. Rodell, Sean P. Arlauckas, Michael F. Cuccarese, et al.
Nature Biomedical Engineering (2018) Vol. 2, Iss. 8, pp. 578-588
Open Access | Times Cited: 884
Christopher B. Rodell, Sean P. Arlauckas, Michael F. Cuccarese, et al.
Nature Biomedical Engineering (2018) Vol. 2, Iss. 8, pp. 578-588
Open Access | Times Cited: 884
Translational Applications of Hydrogels
Santiago Correa, Abigail K. Grosskopf, Hector Lopez Hernandez, et al.
Chemical Reviews (2021) Vol. 121, Iss. 18, pp. 11385-11457
Open Access | Times Cited: 719
Santiago Correa, Abigail K. Grosskopf, Hector Lopez Hernandez, et al.
Chemical Reviews (2021) Vol. 121, Iss. 18, pp. 11385-11457
Open Access | Times Cited: 719
Advances in cancer immunotherapy 2019 – latest trends
Stephan Krüger, Matthias Ilmer, Sebastian Kobold, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 500
Stephan Krüger, Matthias Ilmer, Sebastian Kobold, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 500
HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine
Shuangsang Fang, Lei Dong, Liu Liu, et al.
Nucleic Acids Research (2020) Vol. 49, Iss. D1, pp. D1197-D1206
Open Access | Times Cited: 438
Shuangsang Fang, Lei Dong, Liu Liu, et al.
Nucleic Acids Research (2020) Vol. 49, Iss. D1, pp. D1197-D1206
Open Access | Times Cited: 438
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 307-319
Open Access | Times Cited: 430
Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 307-319
Open Access | Times Cited: 430
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 389-402
Open Access | Times Cited: 413
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 389-402
Open Access | Times Cited: 413
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Zsófia D. Drobni, Raza M. Alvi, Jana Taron, et al.
Circulation (2020) Vol. 142, Iss. 24, pp. 2299-2311
Open Access | Times Cited: 401
Zsófia D. Drobni, Raza M. Alvi, Jana Taron, et al.
Circulation (2020) Vol. 142, Iss. 24, pp. 2299-2311
Open Access | Times Cited: 401
Therapeutic targeting of trained immunity
Willem J. M. Mulder, Jordi Ochando, Leo A. B. Joosten, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 7, pp. 553-566
Open Access | Times Cited: 365
Willem J. M. Mulder, Jordi Ochando, Leo A. B. Joosten, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 7, pp. 553-566
Open Access | Times Cited: 365
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Jun Tang, Jia Xin Yu, Vanessa M. Hubbard-Lucey, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 12, pp. 854-855
Closed Access | Times Cited: 347
Jun Tang, Jia Xin Yu, Vanessa M. Hubbard-Lucey, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 12, pp. 854-855
Closed Access | Times Cited: 347
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Wenting Zhang, Qinghua Huang, Weiwei Xiao, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 293
Wenting Zhang, Qinghua Huang, Weiwei Xiao, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 293
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei, Nana-Ama A.S. Anang, Roshan Sharma, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 45, pp. 22699-22709
Open Access | Times Cited: 283
Spencer C. Wei, Nana-Ama A.S. Anang, Roshan Sharma, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 45, pp. 22699-22709
Open Access | Times Cited: 283
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
Lili Zhang, Magid Awadalla, Syed Mahmood, et al.
European Heart Journal (2020) Vol. 41, Iss. 18, pp. 1733-1743
Open Access | Times Cited: 283
Lili Zhang, Magid Awadalla, Syed Mahmood, et al.
European Heart Journal (2020) Vol. 41, Iss. 18, pp. 1733-1743
Open Access | Times Cited: 283
Treatment of Advanced Melanoma in 2020 and Beyond
Russell W. Jenkins, David E. Fisher
Journal of Investigative Dermatology (2020) Vol. 141, Iss. 1, pp. 23-31
Open Access | Times Cited: 279
Russell W. Jenkins, David E. Fisher
Journal of Investigative Dermatology (2020) Vol. 141, Iss. 1, pp. 23-31
Open Access | Times Cited: 279
Immune Checkpoint Inhibitor-Associated Myocarditis
Sarju Ganatra, Tomas G. Neilan
The Oncologist (2018) Vol. 23, Iss. 8, pp. 879-886
Open Access | Times Cited: 256
Sarju Ganatra, Tomas G. Neilan
The Oncologist (2018) Vol. 23, Iss. 8, pp. 879-886
Open Access | Times Cited: 256
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Jennifer L. Guerriero
Trends in Molecular Medicine (2018) Vol. 24, Iss. 5, pp. 472-489
Open Access | Times Cited: 252
Jennifer L. Guerriero
Trends in Molecular Medicine (2018) Vol. 24, Iss. 5, pp. 472-489
Open Access | Times Cited: 252
Targeting CD39 in cancer
Achim K. Moesta, Xian-Yang Li, Mark J. Smyth
Nature reviews. Immunology (2020) Vol. 20, Iss. 12, pp. 739-755
Closed Access | Times Cited: 250
Achim K. Moesta, Xian-Yang Li, Mark J. Smyth
Nature reviews. Immunology (2020) Vol. 20, Iss. 12, pp. 739-755
Closed Access | Times Cited: 250
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 7, pp. 529-540
Closed Access | Times Cited: 238
Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 7, pp. 529-540
Closed Access | Times Cited: 238
Translational genomics and recent advances in oral squamous cell carcinoma
Annie Wai Yeeng Chai, Kue Peng Lim, Sok Ching Cheong
Seminars in Cancer Biology (2019) Vol. 61, pp. 71-83
Closed Access | Times Cited: 217
Annie Wai Yeeng Chai, Kue Peng Lim, Sok Ching Cheong
Seminars in Cancer Biology (2019) Vol. 61, pp. 71-83
Closed Access | Times Cited: 217
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Rachael M. Zemek, Emma de Jong, Wee Loong Chin, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 501
Open Access | Times Cited: 194
Rachael M. Zemek, Emma de Jong, Wee Loong Chin, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 501
Open Access | Times Cited: 194
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 194
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 194
Engineering patient-specific cancer immunotherapies
Lindsay Scheetz, Kyong Soo Park, Qiao Li, et al.
Nature Biomedical Engineering (2019) Vol. 3, Iss. 10, pp. 768-782
Open Access | Times Cited: 178
Lindsay Scheetz, Kyong Soo Park, Qiao Li, et al.
Nature Biomedical Engineering (2019) Vol. 3, Iss. 10, pp. 768-782
Open Access | Times Cited: 178